Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) have received an average recommendation of “Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $6.25.
Several equities analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $5.50 price target on shares of ZIOPHARM Oncology in a report on Thursday, May 9th. Zacks Investment Research cut ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a report on Saturday, May 18th. Finally, BidaskClub upgraded ZIOPHARM Oncology from a “buy” rating to a “strong-buy” rating in a report on Monday, June 17th.
Institutional investors have recently bought and sold shares of the stock. Aperio Group LLC bought a new position in ZIOPHARM Oncology in the second quarter valued at about $35,000. Harel Insurance Investments & Financial Services Ltd. bought a new position in ZIOPHARM Oncology during the first quarter worth about $35,000. Magnus Financial Group LLC bought a new position in ZIOPHARM Oncology during the first quarter worth about $39,000. Mercer Global Advisors Inc. ADV bought a new position in ZIOPHARM Oncology during the first quarter worth about $48,000. Finally, Niemann Capital Management Inc. bought a new position in ZIOPHARM Oncology during the second quarter worth about $79,000. Institutional investors and hedge funds own 38.95% of the company’s stock.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). During the same quarter last year, the company posted ($0.12) earnings per share. Equities analysts predict that ZIOPHARM Oncology will post -0.33 earnings per share for the current year.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.